$OMCL News

Wells Fargo Maintains Overweight on Omnicell, Lowers Price Target to $50

Keybanc Maintains Overweight on Omnicell, Lowers Price Target to $65

Omnicell, Inc. 2026 Q2 - Results - Earnings Call Presentation

Omnicell, Inc. (OMCL) Q2 2026 Earnings Call Transcript

Omnicell (NASDAQ:OMCL) Q2 Earnings Beat Overshadowed by Disappointing Guidance

Omnicell Sees Q3 Adj EPS $0.35-$0.43 vs $0.47 Est; Sees Sales $301.000M-$307.000M vs $312.528M Est

Omnicell Raises FY2026 Adj EPS Guidance from $1.80-$2.00 to $2.15-$2.30 vs $1.94 Est; Narrows FY2026 Sales Guidance from $1.215B-$1.255B to $1.225B-$1.245B vs $1.248B Est

Omnicell Q2 Adj. EPS $0.94 Beats $0.47 Estimate, Sales $312.208M Beat $310.253M Estimate

The Bull Case For Omnicell (OMCL) Could Change Following New President And ESOP Share Offering

Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026

Nnamdi Njoku Appointed President of Omnicell

Omnicell Appoints COO Nnamdi Njoku As President, Effective July 1

Do Options Traders Know Something About Omnicell Stock We Don't?

Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Omnicell: Why I'm Long Into Q2 Earnings Despite The Bookings Wobble

Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business

Omnicell Shareholders Back Governance Amendment And Long Term Growth Focus

Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know

Omnicell (OMCL) is a Top-Ranked Momentum Stock: Should You Buy?

Omnicell (OMCL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now